



ASX Announcement | 31 August 2020
Noxopharm Limited (ASX:NOX)

Noxopharm Announces Board Changes

- Non-executive director, Dr Ian Dixon, leaves the Noxopharm Board and takes up an appointment to the Nyrada Inc Board as non-executive director.
- The Dixon appointment allows Dr Graham Kelly to step down from his role as non-executive director on the Nyrada Inc Board to focus on his Noxopharm CEO role ahead of a projected period of significant growth.

Sydney 31 August 2020: Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) announces changes to its Board in response to significant commercial opportunities now emerging for the Company.

Dr Graham Kelly, steps down from the Nyrada Board to focus on his role as Noxopharm CEO, although will remain involved as a consultant to the Nyrada Board. Dr Kelly's place on the Nyrada Board will be filled by Dr Ian Dixon.

Kelly said: "Some recent major discoveries such as the ability to convert tumours from cold to hot have meant that Noxopharm is about to step up to another level of activity including a growing engagement with the pharma industry. That means for me the need for more focus and more load-sharing."

"Ian Dixon leaving the NOX Board to fill my vacancy on the Nyrada Board is a bitter-sweet move given that Ian is a founding NOX Board member and as one of Australia's most notable entrepreneurial scientific thinkers, has made a significant contribution over the past 4 years to the ultimate success of Noxopharm. However, as the brains behind the PCSK9-inhibitor program, now a major Nyrada drug program, his move to the Nyrada Board is a positive given the Noxopharm position as the major shareholder in Nyrada."

A search for a replacement for Dr Dixon is underway.

Graham Kelly, CEO, has approved the release of this document to the market on behalf of the Board of Directors.

-ENDS-

About Noxopharm

Noxopharm Limited (ASX:NOX) is an Australian clinical-stage drug development company focused on the treatment of cancer and septic shock.

Veyonda® is the Company's first pipe-line drug candidate currently in Phase 2 clinical trialling. Veyonda® has two main drug actions – inhibition of sphingosine kinase and inhibition of STING signalling. Activity against the former target contributes to its dual-acting oncotoxic and immuno-oncology functions designed to enhance the



effectiveness and safety of standard oncology treatments, i.e., chemotherapies, radiotherapy and immune checkpoint inhibitors. Activity against the latter target provides an anti-inflammatory effect, also contributing to an anti-cancer action, but also potentially blocking sepsis.

The Company's second pipeline candidate is a novel metabotropic glutamate receptor inhibitor for the treatment of brain cancers.

Noxopharm also is the major shareholder of US biotechnology company Nyrada Inc (ASX:NYR).

To learn more, please visit: noxopharm.com

Investor & Corporate enquiries:

Prue Kelly
M: 0459 022 445
E: info@noxopharm.com

Company Secretary:

David Franks
T: +61 2 8072 1400
E: David.Franks@automicgroup.com.au

Media Enquiries

Julia Maguire
The Capital Network
E: julia@thecapitalnetwork.com.au
T: + 61 2 8999 3699

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as "aim", "anticipate", "assume", "believe", "continue", "could", "estimate", "expect", "intend", "may", "plan", "predict", "project", "plan", "should", "target", "will" or "would" or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company's control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.